Lantheus Holdings Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Lantheus Holdings ha aumentado sus beneficios a una tasa media anual de 33%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.5% anual. Los ingresos han ido creciendo a una tasa media de 32.3% al año. La rentabilidad financiera de Lantheus Holdings es de 40%, y sus márgenes netos son de 25.2%.

Información clave

56.0%

Tasa de crecimiento de los beneficios

43.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	34.1%
Rentabilidad financiera	48.7%
Margen neto	33.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

May 10

Lantheus Holdings: Powerful First Quarter

May 05

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

Apr 12

Lantheus Holdings: Undervalued With A Good Outlook

Feb 28

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Feb 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

May 29

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Apr 16

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Feb 27

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Jan 16

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Dec 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Oct 31

Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?

Oct 04

Looking In On Lantheus Holdings

Sep 14

Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent

Aug 25

Lantheus Non-GAAP EPS of $0.89 beats by $0.19, revenue of $223.72M beats by $19.21M

Aug 04

Lantheus Holdings (NASDAQ:LNTH) May Have Issues Allocating Its Capital

Jul 22

Lantheus Holdings Rules The Medical Diagnostics Business World

Jul 06

We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease

Jun 25

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Lantheus Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:LNTH Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	1,366	461	295	95
31 Dec 23	1,296	327	258	62
30 Sep 23	1,206	104	258	318
30 Jun 23	1,125	33	234	316
31 Mar 23	1,027	-18	232	314
31 Dec 22	935	28	234	312
30 Sep 22	801	107	249	51
30 Jun 22	664	32	236	49
31 Mar 22	542	-37	237	47
31 Dec 21	425	-71	209	45
30 Sep 21	390	-34	154	44
30 Jun 21	376	-27	145	44
31 Mar 21	341	-8	103	36
31 Dec 20	339	-13	98	30
30 Sep 20	335	0	100	25
30 Jun 20	332	12	101	18
31 Mar 20	352	25	107	19
31 Dec 19	347	32	103	20
30 Sep 19	344	35	98	20
30 Jun 19	347	39	94	20
31 Mar 19	347	42	93	18
31 Dec 18	343	41	93	17
30 Sep 18	338	124	94	16
30 Jun 18	329	124	92	16
31 Mar 18	333	127	89	17
31 Dec 17	331	123	92	18
30 Sep 17	324	31	84	18
30 Jun 17	318	27	81	17
31 Mar 17	307	21	79	15
31 Dec 16	302	27	75	12
30 Sep 16	299	26	75	12
30 Jun 16	300	27	74	11
31 Mar 16	295	-5	79	11
31 Dec 15	293	-15	79	14
30 Sep 15	299	-18	77	16
30 Jun 15	301	-25	79	17
31 Mar 15	303	-2	72	17
31 Dec 14	302	-4	72	14
30 Sep 14	296	-16	72	14
30 Jun 14	291	-30	68	17
31 Mar 14	286	-43	67	22
31 Dec 13	284	-62	68	30
30 Sep 13	284	-59	70	35
30 Jun 13	288	-72	71	39

Ingresos de calidad: LNTH tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: LNTH pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lLNTH han crecido significativamente en un 33% al año.

Acelerando crecimiento: LNTH ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: LNTH ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).

Lantheus Holdings Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Recent updates

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Consensus EPS estimates increase by 27%

Lantheus Holdings: Powerful First Quarter

Price target increased by 8.3% to US$106

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

CFO & Treasurer notifies of intention to sell stock

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Chairman of the Board notifies of intention to sell stock

Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients

Investor sentiment improves as stock rises 15%

Lantheus Holdings: Undervalued With A Good Outlook

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Full year 2023 earnings: EPS exceeds analyst expectations

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)

Now 25% undervalued after recent price drop

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings

Investor sentiment deteriorates as stock falls 22%

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Price target decreased by 7.7% to US$108

Now 31% undervalued after recent price drop

CFO & Treasurer notifies of intention to sell stock

Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing

A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

CEO & Director notifies of intention to sell stock

Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?

New major risk - Earnings quality

New major risk - Revenue and earnings growth

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

CEO & Director notifies of intention to sell stock

Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New minor risk - Earnings quality

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?

Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging

Insufficient new directors

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Chief Administrative Officer notifies of intention to sell stock

Price target increased by 7.4% to US$120

Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Business Officer notifies of intention to sell stock

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

CEO & Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Investor sentiment improves as stock rises 17%

Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc.

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

Senior VP notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Desglose de ingresos y gastos
Beta